2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases
Top Cited Papers
Open Access
- 23 February 2020
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 72 (4) , 461-488
Abstract
Objective: To develop an evidence‐based guideline on contraception, assisted reproductive technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy (HRT), pregnancy assessment and management, and medication use in patients with rheumatic and musculoskeletal disease (RMD).Methods: We conducted a systematic review of evidence relating to contraception, ART, fertility preservation, HRT, pregnancy and lactation, and medication use in RMD populations, using Grading of Recommendations Assessment, Development and Evaluation methodology to rate the quality of evidence and a group consensus process to determine final recommendations and grade their strength (conditional or strong). Good practice statements were agreed upon when indirect evidence was sufficiently compelling that a formal vote was unnecessary.Results: This American College of Rheumatology guideline provides 12 ungraded good practice statements and 131 graded recommendations for reproductive health care in RMD patients. These recommendations are intended to guide care for all patients with RMD, except where indicated as being specific for patients with systemic lupus erythematosus, those positive for antiphospholipid antibody, and/or those positive for anti‐Ro/SSA and/or anti‐La/SSB antibodies. Recommendations and good practice statements support several guiding principles: use of safe and effective contraception to prevent unplanned pregnancy, pre‐pregnancy counseling to encourage conception during periods of disease quiescence and while receiving pregnancy‐compatible medications, and ongoing physician‐patient discussion with obstetrics/gynecology collaboration for all reproductive health issues, given the overall low level of available evidence that relates specifically to RMD.Conclusion: This guideline provides evidence‐based recommendations developed and reviewed by panels of experts and RMD patients. Many recommendations are conditional, reflecting a lack of data or low‐level data. We intend that this guideline be used to inform a shared decision‐making process between patients and their physicians on issues related to reproductive health that incorporates patients’ values, preferences, and comorbidities.Keywords
This publication has 181 references indexed in Scilit:
- Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality?Arthritis Care & Research, 2010
- A Systematic Review and Meta-Analysis of Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus and Lupus NephritisClinical Journal of the American Society of Nephrology, 2010
- Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancyJournal of Thrombosis and Haemostasis, 2010
- Prospective Evaluation of Fetuses With Autoimmune-Associated Congenital Heart Block Followed in the PR Interval and Dexamethasone Evaluation (PRIDE) StudyThe American Journal of Cardiology, 2009
- Systemic lupus erythematosus pregnancies: a case series from a tertiary, East Malaysian hospitalLupus, 2009
- Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysisBMJ, 2008
- Pregnancy in systemic lupus erythematosus: a retrospective study from a developing communityClinical Rheumatology, 2007
- A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virusAmerican Journal of Obstetrics and Gynecology, 2007
- Colchicine in breast milk of patients with familial mediterranean feverArthritis & Rheumatism, 1996
- CONTRACEPTIVE PRACTICE IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUSRheumatology, 1993